Corcoran, Ryan B.

TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast Cancer

Abelman, R. O., Wu, B., Barnes, H., Medford, A., Norden, B., Putur, A., Bitman, E., Thant, W., Liu, T., Weipert, C., et al. (2025) · Clinical Cancer Research

Cancer therapeutics and mechanismsLung Cancer Treatments and Mutations

Cited by 61

P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation

Tabernero, J., Bendell, J., Corcoran, R., Kopetz, S., Lee, J., Davis, M., Christensen, J., Chi, A., Kheoh, T., & Yaeger, R. (2021) · Annals of Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 28

Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours

Corcoran, R. B., Do, K. T., Cleary, J. M., Parikh, A. R., Yeku, O. O., Weekes, C. D., Veneris, J., Ahronian, L. G., Mauri, G., Van Seventer, E. E., et al. (2019) · Annals of Oncology

Melanoma and MAPK PathwaysCell death mechanisms and regulation

Cited by 17